“There are no remaining legal or regulatory barriers, and the company is launching immediately,” Viatris has confirmed, following its landmark approval for the first generic version of AbbVie’s Restasis (cyclosporine) 0.05% ophthalmic emulsion.
Viatris Readies Restasis Launch – So Where Are The Others?
‘No Remaining Legal Or Regulatory Barriers’ Notes F-T-M Viatris
Viatris management has confirmed plans to begin shipping its long-awaited generic Restasis product immediately. Analysts continue to speculate that the approval could remove a hurdle for other firms, if they can get their ANDAs over the line.
More from Products
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
More from Generics Bulletin
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.